



**PRELIMINARY FINAL REPORT OF
VITA LIFE SCIENCES LIMITED
FOR THE YEAR ENDED 31 DECEMBER 2017**

This Preliminary Final Report is provided to the Australian Securities Exchange ("ASX") under ASX Listing Rule 4.3A

Current Reporting Period:

Financial Year Ended 31 December 2017

Previous Corresponding Period:

Financial Year Ended 31 December 2016

**Vita Life Sciences Limited and its Controlled Entities
ABN 35 003 190 421**

Contents

Results for announcement to the market	3
Commentary on Results	4
Consolidated Statement of Comprehensive Income	6
Consolidated Statement of Financial Position	7
Consolidated Statement of Cash Flows	8
Consolidated Statement of Changes in Equity	9
Notes to the Financial Statements	11
Compliance Statement	43

Name of Entity: Vita Life Sciences Limited

ABN: 35 003 190 421

Results for announcement to the market

		Percentage Change	2017
		%	A\$'000
Revenue	down	0%	37,738
Profit from continuing operations before tax and finance costs	down	-18%	4,698
Profit before income tax	down	-17%	4,676
Net profit after tax	down	-14%	2,856
Net profit attributable to members	down	-14%	2,863

Dividends (distributions)		Franked amount per security
Interim dividend per share	1.5 cents	1.5 cents
Final dividend per share	2.25 cents	2.25 cents

Ex-Dividend date for the purpose of receiving the dividend

19-Mar-18

Record date for determining entitlements to dividends

20-Mar-18

Payment date

29-Mar-18

The Company's dividend reinvestment plan remains suspended, and as such does not apply to the final dividend.

Commentary on Results

Brief explanation of any of the figures above necessary to enable the figures to be understood

Vita Life Sciences:

- Full year sales revenue of \$37.7m consistent with FY2016
- Adjusted EBIT for full year: \$5.6m before non-recurring share options expense of \$0.9m (2016 \$5.7m)
- Gross Operating Cashflow/ EBITDA (adjusted for non-cash option expense) of 100%
- Strong balance sheet
- Final dividend of 2.25 cents per share fully franked. Full year dividend of 3.75 cents per share fully franked (2016: 3.75 cents per share)

The Company continued to build on its net cash balance sheet, while:

- Returning \$2.3m to shareholders through dividend payments and the share buyback; and
- Reducing the Group's only borrowings (associated with the Malaysian office facility) by \$0.3m to \$2.2m.

Adjusted EBIT Year ended 31 December 2017

	Total \$'000
Reported EBIT	4,698
Share options expense*	932
Adjusted EBIT	5,630

*Substantially non-recurring

Review of Business Operations

The Group recorded revenue of \$37.7m consistent with FY2016. Reported EBIT of \$4.7m was impacted by a \$0.9m charge for options issued in relation to the Group's China business. Overall, the underlying operating performance of the business was in line with expectations. Most pleasingly, EBIT contributions from our Asian business, excluding China, increased by 31% to \$2.54m in FY2017 during this period.

2017 was Mr Andrew O'Keefe's first year as Managing Director and, it was imperative for him to drive and shape a growth agenda for the business moving forward. A major step in this process was to complete a strategic review, focusing on organisational structure, distribution partnerships, and capital investment modelling.

One major recommendation, was the need to build out and strengthen the senior management team within the business. The first major appointment was Mr Chin Khoo to the position of Group CFO in May 2017. Mr Khoo provides strong financial expertise and is a great asset to the organisation. The second major appointment was Dr Edward Choo as the CEO South East Asia in October 2017. This appointment was a significant step in driving the performance of the business within this region. The growth opportunities remain significant, and a rejuvenated focus is required to drive the performance. Dr Edward Choo has certainly made a strong start and heavily influenced fourth quarter results. To round out the leadership positions, Mrs Melissa Pereira was appointed as the Group's Head of Marketing in 2017. The Group's future marketing and branding strategies will play a vital role in developing a stronger relationship between our brands and consumers moving into 2018.

The new leadership structure brings together a combination of highly competent individuals, with the capabilities to meet the Company's future growth aspirations.

Commentary on Results (continued)

During FY2017 Vita Life Sciences announced a strategic partnership with the Jointown Pharmaceutical Group, who were appointed the exclusive distributor for the Herbs of Gold brand in mainland China. Whilst sales to China remained low in FY2017, the Herbs of Gold brand is now available in over 10 major e-commerce platforms. Continued investment will be required to further increase revenues from this market.

Lastly, the Company had previously announced its intention to build a packing and laboratory facility within the new Malaysian building. After completing a final commercial assessment, it was determined this project would not generate a positive return based on existing volumes and, the installation of the plant was deferred until volumes warrant. The business has now reallocated this space to hold finished goods and provides direct distribution capabilities as required.

FY2018 will be the second year of a three-year strategic plan set by the Board whereby the Company aims to grow future revenues. As outlined below, it is planned to increase investment in both advertising and promotional activities, whilst broadening distribution channels within key markets. This strategy may impact profitability in the short term, with a view to increase profitability in the medium term. The Board of Directors will provide further guidance mid-way through the year.

Divisional Results

Australia

Revenue from Australian base business was maintained with sales of \$15.6m (2016: \$15.6m) in a competitive environment. Export sales to China remains an important strategic pillar for the Group's growth aspirations and improved performance is anticipated in FY2018. Consequently, for FY2018, the business plan is to increase marketing and branding investment across the Australian and Chinese markets to grow future revenues. This strategy aims to create broader brand awareness amongst consumers, both domestically and internationally.

Malaysia and Singapore

The Malaysian business was a standout performer for the Group. In local currency revenue grew by 6.7% over FY2016. The Malaysian business experienced a turnaround in both sales and EBIT contributions, however most of the growth was negated by the weaker Malaysian Ringgit.

Singapore revenue declined by 1% in Australian dollars in FY2017 compared to FY2016. The business was impacted by challenging trading conditions which meant advertising and promotional expenses were increased to maintain retail support.

Other Asia

Revenue in the Group's expanding markets, namely Vietnam, Thailand and Indonesia, grew to \$2.5m FY2017, or by 15% when compared to FY2016. Strong growth was recorded in Vietnam with modest growth in Thailand. Indonesia remains a challenging market, which requires continued investment and revised distribution pathways.

Consolidated Statement of Comprehensive Income

For the year ended 31 December 2017	Notes	Consolidated	
		2017 \$'000	2016 \$'000
CONTINUING OPERATIONS			
Sale of goods		37,738	37,818
Cost of sales		(12,122)	(11,660)
Gross profit		25,616	26,158
Other income	3 (a)	1	242
Distribution expenses		(3,415)	(3,438)
Marketing expenses		(2,678)	(2,708)
Occupancy expenses		(780)	(921)
Administrative expenses	3 (b)	(12,704)	(13,275)
Other expenses	3 (c)	(412)	(368)
Share options expense	3 (d)	(932)	-
Share of associate's profit		2	12
Profit from continuing operations before interest and taxes		4,698	5,702
Finance income	3 (e)	113	100
Finance expenses	3 (f)	(135)	(165)
Profit before income tax		4,676	5,637
Income tax expense	5	(1,820)	(2,301)
Net profit for the year		2,856	3,336
Other comprehensive income after income tax			
Items that will be reclassified subsequently to profit or loss when specific conditions are met:			
Exchange differences on translating foreign controlled entities		225	(523)
Other comprehensive income/ (loss) for the year, net of income tax		225	(523)
Total comprehensive income for the year		3,081	2,813
Net profit/(loss) for the year attributable to:			
Non-controlling interest		(7)	(7)
Members of the parent		2,863	3,343
		2,856	3,336
Total comprehensive income attributable to:			
Non-controlling interest		(7)	(1)
Members of the parent		3,088	2,814
		3,081	2,813
Earnings per share (cents per share)			
- basic earnings per share	4	5.21	6.06
- diluted earnings per share	4	5.21	5.88

The accompanying notes should be read in conjunction with the above Statement of Comprehensive Income

Consolidated Statement of Financial Position

As at 31 December 2017	Notes	Consolidated	
		2017 \$'000	2016 \$'000
ASSETS			
Current Assets			
Cash and cash equivalents	6	9,965	9,411
Trade and other receivables	7	6,662	6,234
Inventories	8	5,176	5,421
Other assets	9	505	683
Total Current Assets		22,308	21,749
Non Current Assets			
Other assets	9	7	23
Investment in associates	10	947	925
Property, plant and equipment	11	9,409	9,381
Intangible assets	12	60	76
Deferred tax assets	5 (c)	223	205
Total Non Current Assets		10,646	10,610
Total Assets		32,954	32,359
LIABILITIES			
Current Liabilities			
Trade and other payables	13	4,413	4,208
Interest bearing loans and borrowings	14	290	279
Current tax liability		790	1,758
Provisions	15	586	602
Total Current Liabilities		6,079	6,847
Non Current Liabilities			
Deferred Tax Liability	5 (c)	52	51
Interest bearing loans and borrowings	14	1,927	2,181
Provisions	15	103	105
Total Non Current Liabilities		2,082	2,337
Total Liabilities		8,161	9,184
Net Assets		24,793	23,175
EQUITY			
Contributed equity	16	44,498	44,692
Accumulated losses		(19,789)	(20,590)
Employee share based payments reserve		594	733
Share options reserve	16(d)	932	-
Foreign currency translation reserve		(1,477)	(1,702)
Parent entity interest		24,758	23,133
Non-controlling interest		35	42
Total Equity		24,793	23,175

The accompanying notes should be read in conjunction with the above Statement of Financial Position

Consolidated Statement of Cash Flows

For the year ended 31 December 2017	Notes	Consolidated	
		2017 \$'000	2016 \$'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		40,767	41,583
Payments to suppliers and employees		(34,761)	(36,188)
Income tax paid		(2,804)	(689)
Interest received		113	100
Borrowing costs		(97)	(112)
Net cash flows provided by operating activities	6 (d)	3,218	4,694
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		(193)	(2,214)
Net cash flows used in investing activities		(193)	(2,214)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from external borrowings		-	2,741
Repayment of external borrowings		(287)	(3,091)
Dividends Paid		(2,063)	(2,070)
Shares bought back (net of costs)		(194)	(219)
Net cash flows used in financing activities		(2,544)	(2,639)
Net increase/ (decrease) in cash and cash equivalents		481	(159)
Net foreign exchange differences		73	(164)
Cash and cash equivalents at beginning of the year		9,411	9,734
Cash and cash equivalents at end of the year	6	9,965	9,411

Reconciliation of liabilities arising from financing activities

	Notes	2017 \$'000	Cashflows \$'000	Non-cash changes Foreign exchange movement \$'000	2016 \$'000
Interest bearing loans and borrowings	14	2,217	(287)	44	2,460

The accompanying notes should be read in conjunction with the above Statement of Cash Flows

Consolidated Statement of Changes in Equity

	Note	Contributed Equity \$'000	Employee Share Based Payments Reserve \$'000	Share Options Reserve \$'000	Accumulated Losses \$'000	Foreign Currency Translation Reserve \$'000	Attributable to Equity Holders of Parent \$'000	Non- controlling Interest \$'000	Total \$'000
Balance at 1 January 2017		44,692	733	-	(20,590)	(1,702)	23,133	42	23,175
Comprehensive income									
Profit attributable to members of parent entity		-	-	-	2,863	-	2,863	(7)	2,856
Other comprehensive income/(loss) for the year		-	-	-	-	225	225	-	225
Total comprehensive income for the year		-	-	-	2,863	225	3,088	(7)	3,081
Transactions with owners, in their capacity as owners									
Shares bought back		(193)	-	-	-	-	(193)	-	(193)
Employee share based (income)		-	(139)	-	-	-	(139)	-	(139)
Share options expense	16(d)	-	-	932	-	-	932	-	932
Dividends paid	16(f)	-	-	-	(2,063)	-	(2,063)	-	(2,063)
Total transactions with owners		(193)	(139)	932	(2,063)	-	(1,463)	-	(1,463)
Balance at 31 December 2017		44,499	594	932	(19,790)	(1,477)	24,758	35	24,793

The accompanying notes should be read in conjunction with the above Statement of Changes in Equity

Consolidated Statement of Changes in Equity (continued)

	Note	Contributed Equity \$'000	Employee Share Based Payments Reserve \$'000	Accumulated Losses \$'000	Foreign Currency Translation Reserve \$'000	Attributable to Equity Holders of Parent \$'000	Non- controlling Interest \$'000	Total \$'000
Balance at 1 January 2016		44,911	958	(21,863)	(1,180)	22,826	50	22,876
Comprehensive income								
Profit attributable to members of parent entity		-	-	3,343	-	3,343	(7)	3,336
Other comprehensive income/(loss) for the year		-	-	-	(522)	(522)	(1)	(523)
Total comprehensive income for the year		-	-	3,343	(522)	2,821	(8)	2,813
Shares bought back		(219)	-	-	-	(219)	-	(219)
Repayment of loans on Employee share option scheme		-	-	-	-	-	-	-
Employee share option scheme		-	(225)	-	-	(225)	-	(225)
Dividends paid	16(f)	-	-	(2,070)	-	(2,070)	-	(2,070)
Total transactions with owners		(219)	(225)	(2,070)	-	(2,514)	-	(2,514)
Balance at 31 December 2016		44,692	733	(20,590)	(1,702)	23,133	42	23,175

The accompanying notes should be read in conjunction with the above Statement of Changes in Equity

Notes to the Financial Statements

For the Year Ended 31 December 2017

1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of preparation

The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards, Australian Accounting Interpretations, other authoritative pronouncements of the Australian Accounting Standards Board (AASB) and the *Corporations Act 2001*. The Group is a for-profit entity for financial reporting purposes under Australian Accounting Standards.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in financial statements containing relevant and reliable information about transactions, events and conditions. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards as issued by the IASB. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise.

Except for cash flow information, the financial statements have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

(b) Statement of compliance

The financial report complies with Australian Accounting Standards, which include Australian equivalents to International Financial Reporting Standards ("AIFRS"). Compliance with AIFRS ensures that the financial report, comprising the financial statements and notes thereto, complies with International Financial Reporting Standards ("IFRS").

(c) Basis of consolidation

The consolidated financial statements comprise the financial statements of Vita Life Sciences Limited and its subsidiaries ("the Group") as at 31 December 2017. Interests in associates are equity accounted and are not part of the consolidated Group.

Subsidiaries are all those entities over which the Group has the power to govern the financial and operating policies so as to obtain benefits from their activities. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether a group controls another entity.

The financial statements of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies.

In preparing the consolidated financial statements, all intercompany balances and transactions, income and expenses and profit and losses resulting from intra-group transactions have been eliminated in full.

Subsidiaries are fully consolidated from the date on which control is obtained by the Group and cease to be consolidated from the date on which control is transferred out of the Group.

Investments in subsidiaries held by Vita Life Sciences Limited are accounted for at cost in the separate financial statements of the parent entity.

The acquisition of subsidiaries is accounted for using the purchase method of accounting. The purchase method of accounting involves allocating the cost of the business combination to the fair value of the assets acquired and the liabilities and contingent liabilities assumed at the date of acquisition.

Minority interests represent the interests in Vita Life Sciences (Thailand) Co. Ltd and Vitahealth (Thailand) Co. Ltd not held by the Group. Minority interests are allocated their share of net profit or loss after tax in the statement of comprehensive income and are presented within Equity in the consolidated statement of financial position, separately from the parent shareholders' equity.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Summary of Significant Accounting Policies (continued)

(d) Business combinations

The purchase method of accounting is used to account for all business combinations regardless of whether equity instruments or other assets are acquired. Cost is measured as the fair value of the assets given, shares issued or liabilities incurred or assumed at the date of exchange plus cost directly attributable to the combination. Where equity instruments are issued in a business combination, the fair value of the instruments is their published market price as at the date of exchange. Transaction costs arising from the issue of equity instruments are recognised directly in equity.

Except for non-current assets classified as held for sale (which are measured at fair value less costs to sell), all identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. The excess of the cost of the business combination over the net fair value of the Group's share of the identifiable net assets acquired is recognised as goodwill. If the cost of acquisition is less than the Group's share of the net fair value of the identifiable net assets of the subsidiary, the difference is recognised as a gain in the statement of comprehensive income, but only after a reassessment of the identification and measurement of the net assets acquired.

Where settlement of any part of the consideration is deferred, the amounts payable in the future are discounted to their present values as at the date of exchange. The discount rate used is the entity's incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions.

(e) Foreign currency translation

(i) Functional and presentation currency

Both the functional and presentation currency of Vita Life and its Australian subsidiaries are in Australian dollars (\$).

The functional currency of the main operating overseas subsidiaries Vita Healthcare Asia Pacific Sdn Bhd, VitaHealth Malaysia Sdn Bhd, Herbs of Gold Sdn Bhd, Vita Life Sciences Sdn Bhd and Pharma Direct Sdn Bhd are in Malaysian Ringgit (MYR), whilst VitaHealth Asia Pacific (S) Pte Ltd, Herbs of Gold (S) Pte Ltd and Vita Corporation Pte Limited are in Singapore dollars (SGD).

(ii) Transactional and balances

Transactions in foreign currencies are initially recorded in the functional currency by applying the exchange rates ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange ruling at the balance sheet date.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate as at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rate at the date when the fair value was determined.

The exchange differences arising on the retranslation are taken directly to a separate component of equity.

On disposal of a foreign entity, the deferred cumulative amount recognised in equity relating to that particular foreign operation is recognised in the statement of comprehensive income.

(f) Cash and cash equivalents

Cash and cash equivalents in the statement of financial position comprise cash at bank and on hand and short-term deposits with an original maturity of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

For the purposes of the Statement of Cash Flows, cash and cash equivalents consist of cash and cash equivalents as defined above, net of outstanding bank overdrafts.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Summary of Significant Accounting Policies (continued)

(g) Trade and other receivables

Trade receivables, which generally have 30-90 day terms, are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less an allowance for impairment.

Collectability of trade receivables is reviewed on an ongoing basis at an operating unit level. Individual debts that are known to be uncollectible are written off when identified. An impairment provision is recognised when there is objective evidence that the Group will not be able to collect the receivable. Financial difficulties of the debtor or default payments are considered objective evidence of impairment. The amount of the impairment loss is the receivable carrying amount compared to the present value of estimated future cash flows, discounted at the original effective interest rate.

(h) Inventory

Inventories including raw materials are valued at the lower of cost and net realisable value. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated selling costs.

Costs incurred in bringing each product to its present location and condition is accounted for as follows:

Raw materials – purchase cost on a first-in, first-out basis.

Finished goods and work-in-progress – cost of direct materials and labour and a proportion of manufacturing overheads based on normal operating capacity but excluding borrowing costs.

(i) Property, plant and equipment

Plant and equipment is measured at cost less accumulated depreciation and impairment losses.

The cost of fixed assets constructed within the economic entity includes the cost of materials, direct labour, borrowing costs and an appropriate proportion of fixed and variable overheads. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be reliably. All other repairs and maintenance are charged to the statement of comprehensive income during the financial period in which they are incurred.

Depreciation

The depreciable amounts of all fixed assets including capitalised lease assets are depreciated on a straight-line basis over the estimated useful lives. Leasehold improvements are depreciated over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements.

Depreciation is calculated on a straight-line basis over the estimated useful life of the asset as follows:

	<u>Rate</u>	<u>Method</u>
Buildings	2%	Straight-line method
Plant and equipment	10-33%	Straight-line method
Leasehold Improvements	20-50%	Straight-line method
Motor Vehicles	20-50%	Straight-line method

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the item) is included in the statement of comprehensive income in the year the item is derecognised.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Summary of Significant Accounting Policies (continued)

(j) Goodwill and Intangibles

Goodwill

Goodwill acquired in a business combination is initially measured at cost being the excess of the cost of the business combination over the Group's interest in the net fair value of the acquiree's identifiable assets, liabilities and contingent liabilities.

From the initial recognition, goodwill is measured at cost less any accumulated impairment losses.

For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's cash-generating units, or groups of cash-generating units, that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the Group are assigned to those units or group of units.

Impairment is determined by assessing the recoverable amount of the cash-generating unit (group of cash-generating units), to which the goodwill relates.

When the recoverable amount of the cash-generating unit (group of cash-generating units) is less than the carrying amount, an impairment loss is recognised. When goodwill forms part of a cash-generating unit (group of cash-generating units) and an operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal of the operation. Goodwill disposed of in this manner is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained. Impairment losses recognised for goodwill are not subsequently reversed.

Intangibles

Intangible assets acquired separately are capitalised at cost and from a business combination are capitalised at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses. Internally generated intangible assets, excluding development costs, created within the business are not capitalised and expenditure is charged against profits in the year in which the expenditure is incurred.

The useful lives of these intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are amortised over the useful life and tested for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the assets are accounted for prospectively by changing the amortisation period or method, as appropriate, which is a change in accounting estimate. The amortisation expense on intangible assets with finite lives is recognised in profit or loss in the expense category consistent with the function of the intangible asset.

Intangible assets with indefinite useful lives are tested for impairment annually either individually or at that cash-generating unit level consistent with the methodology outlined for goodwill above. Such intangibles are not amortised. The useful life of an intangible asset with an indefinite life is reviewed each reporting period to determine whether indefinite life assessment continues to be supportable. If not, the change in the useful life assessment from indefinite to finite is accounted for as a change in an accounting estimate and is thus accounted for on prospective basis.

A summary of the policies applied to the Group's intangible asset is as follows:

	<u>Patents and licences</u>	<u>Development costs</u>
Useful lives	Indefinite	Finite
Method used	Not depreciated or revalued	3 years – Straight line
Internally generated/ Acquired	Acquired	Internally generated
Impairment test / Recoverable amount testing	Annually and where an indicator of impairment exists	Amortisation method reviewed at each financial year-end annually for indicator of impairment

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Summary of Significant Accounting Policies (continued)

(k) Impairment of non-financial assets other than goodwill

Intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicated that the carrying amount may not be recoverable.

An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. Recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest level for which there are separately identifiable cash inflows that are largely independent of the cash inflows from other assets or group of assets (cash-generating units). Non-financial assets other than goodwill that suffered impairment are tested for possible reversal of the impairment whenever events or changes in circumstances indicate that the impairment may have reversed.

(l) Trade and other payables

Trade payables and other payables are carried at amortised costs and represent liabilities for goods and services provided to the Group prior to the end of the financial year that are unpaid and arise when the Group becomes obliged to make future payments in respect of the purchase of these goods and services. Trade payables are normally settled within 30 to 90 days.

(m) Interest bearing loans and borrowings

All loans and borrowings are initially recognised at cost, being the fair value of the consideration received net of issue costs associated with the borrowing.

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the effective interest method. Amortised cost is calculated by taking into account any issue costs and any discount or premium on settlement.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.

Borrowing costs

Borrowing costs are recognised as an expense when incurred. Borrowing costs that are directly attributable to the acquisition, construction or production of assets that necessarily take a substantial period of time to prepare for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale.

(n) Provisions

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of comprehensive income net of any reimbursement.

If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

(o) Employee entitlements

Provision is made for employee benefits accumulated as a result of employees rendering services up to the reporting date. These benefits include wages and salaries, annual leave and long service leave.

Employee benefits expected to be settled within twelve months of the reporting date are measured at their nominal amounts based on remuneration rates which are expected to be paid when the liability is settled plus related on-costs. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. In determining the present value of future cash outflows, the market yield as at the reporting date on national government bonds, which have terms to maturity approximating the terms of the related liability, are used.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Summary of Significant Accounting Policies (continued)

(o) Employee entitlements (continued)

Employee benefit expenses and revenues arising in respect of wages and salaries, non-monetary benefits, annual leave, long service leave and other leave benefits; and other types of employee benefits are recognised against profits on a net basis in their respective categories.

(p) Issued capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the gross proceeds.

(q) Leases

Finance Leases

Leases of fixed assets, which substantially transfer to the Group all risks and benefits incidental to ownership of the leased item, but not the legal ownership, are classified as finance leases. Finance leases are capitalised at the inception of the lease at the fair value of the leased property or, if lower, at the present value of the minimum lease payments. Leased assets are depreciated over the shorter of the estimated useful life of the asset or the lease term. Lease payments are apportioned between the finance charges and reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are charged directly against income.

Operating Leases

Leases where the lessor retains substantially all the risks and benefits of ownership of the asset are classified as operating leases. Operating lease payments are recognised as an expense in the statement of comprehensive income on a straight-line basis over the lease term. Lease incentives under operating leases are recognised as a liability and amortised on a straight-line basis over the life of the lease.

(r) Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognised:

Sale of goods

Revenue is recognised (net of returns, discounts and allowances excluding distributors cost) when the significant risks and rewards of ownership of the goods have passed to the buyer and can be measured reliably.

Consequently, transfers of goods to major distributors are considered as consignment inventory and revenue is only recognised upon the achievement of "in-market" sales.

Interest

Revenue is recognised as the interest accrues (using the effective interest rate method, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial instrument) to the net carrying amount of the financial asset.

Dividends

Revenue is recognised when the Group's right to receive the payment is established.

(s) Taxes

Current tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the current period's taxable income. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at balance sheet date.

Deferred income tax is provided on all temporary differences at the balance sheet date between the tax base of assets and liabilities and their carrying amounts for financial reporting purposes.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Summary of Significant Accounting Policies (continued)

(s) Taxes (continued)

Deferred income tax liabilities are recognised for all taxable temporary differences:

- except where the deferred income tax liability arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- in respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, except where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred income tax assets are recognised for all deductible temporary differences, carry-forward of unused tax assets and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry-forward of unused tax assets and unused tax losses can be utilised:

- except where the deferred income tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- in respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are only recognised to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred income tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised.

Unrecognised deferred income tax assets are reassessed at each balance sheet date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the balance sheet date.

Tax consolidation

The Company is the head entity of the tax consolidated group comprising all the Australian wholly owned subsidiaries. The implementation date for the tax consolidated group was 30 June 2003.

Current tax expense/income, deferred tax liabilities and deferred tax assets arising from temporary differences of the members of the tax consolidated group are recognised in the separate financial statements of the members of the tax consolidated group using a "stand-alone basis without adjusting for intercompany transactions" approach by reference to the carrying amounts of assets and liabilities in the separate financial statements of each entity and the tax values applying under consolidation.

Any current tax Australian liabilities (or assets) and deferred tax assets arising from unused tax losses of the subsidiaries is assumed by the head entity in the tax consolidated group and are recognised as amounts payable (receivable) to (from) other entities in the tax consolidated group. Any difference between these amounts is recognised by the head entity as an equity contribution or distribution.

The Company recognises deferred tax assets arising from unused tax losses of the tax consolidated group to the extent that it is probable that future taxable profits of the tax consolidated group will be available against which the asset can be utilised.

Any subsequent period adjustments to deferred tax assets arising from unused tax losses as a result of revised assessments of the probability of recoverability is recognised by the head entity only.

(t) Other taxes

Revenues, expenses and assets are recognised net of the amount of Goods and Services Tax ("GST") except:

- where the GST incurred is not recoverable from the Australian Taxation Office ("ATO"), and is therefore recognised as part of the asset's cost or as part of the expense item.
- Receivables and payables are stated inclusive of GST.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Summary of Significant Accounting Policies (continued)

(t) Other taxes (continued)

The net amount of GST recoverable from, or payable to, the ATO is included as part of receivables or payables in the statement of financial position. Cash flows are presented in the Statement of Cash Flow on a gross basis and the GST component of cash flows arising from investing and financing activities, which is recoverable from, or payable to the taxation authority are classified as operating cash flows.

(u) Financial instruments

Financial instruments are initially measured at cost on trade date, which includes transaction costs, when the related contractual rights or obligations exist. Subsequent to initial recognition these instruments are measured as set out below.

Financial assets at fair value through profit and loss

A financial asset is classified in this category if acquired principally for the purpose of selling in the short term, or if so designated by management and within the requirement of AASB139: Recognition and Measurement of Financial Instruments.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are stated at amortised cost using the effective interest rate method.

De-recognition of financial instruments

Financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is derecognised when:

- the rights to receive cash flows from the asset have expired;
- the Group retains the right to receive cash flows from the asset, but has assumed an obligation to pay them in full without material delay to a third party under a 'pass-through' arrangement; or
- the Group has transferred its rights to receive cash flows from the asset and either (a) has transferred substantially all the risks and rewards of the asset, or (b) has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset and has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the asset is recognised to the extent of the Group's continuing involvement in the asset. Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration received that the Group could be required to repay.

Financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a de-recognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in profit or loss.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed. Any subsequent reversal of an impairment loss is recognised in profit or loss, to the extent that the carrying value of the asset does not exceed its amortised cost at the reversal date.

Financial assets carried at amortised cost

If there is objective evidence that an impairment loss on loans and receivables carried at amortised cost has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not been incurred) discounted at the financial asset's original effective interest rate (i.e. the effective interest rate computed at initial recognition). The carrying amount of the asset is reduced either directly or through use of an allowance account. The amount of the loss is recognised in profit or loss.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Summary of Significant Accounting Policies (continued)

(u) Financial instruments (continued)

The Group first assesses whether objective evidence of impairment exists individually for financial assets that are individually significant, and individually or collectively for financial assets that are not individually significant. If it is determined that no objective evidence of impairment exists for an individually assessed financial asset, whether significant or not, the asset is included in a group of financial assets with similar credit risk characteristics and that group of financial assets is collectively assessed for impairment. Assets that are individually assessed for impairment and for which an impairment loss is or continues to be recognised are not included in a collective assessment of impairment.

Financial assets carried at cost

If there is objective evidence that an impairment loss has been incurred on an unquoted equity instrument that is not carried at fair value (because its fair value cannot be reliably measured), or on a derivative asset that is linked to and must be settled by delivery of such an unquoted equity instrument, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the current market rate of return for a similar financial asset.

(v) Earnings per share

Basic earnings per share

Basic earnings per share is determined by dividing the net profit/(loss) after income tax attributable to members of the Company by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year.

Diluted earnings per share

Diluted earnings per share adjust the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

(w) Share-based payment transactions

(i) Equity settled transactions:

The Group provides benefits to its employees (including key management personnel) in the form of share-based payments, whereby employees render services in exchange for shares or rights over shares (equity-settled transactions).

The cost of the equity-settled transactions with employees is measured by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined using the Black-Scholes model. In valuing equity-settled transactions, no account is taken of any vesting conditions, other than conditions linked to the price of the shares of Vita Life Sciences Limited (market conditions) if applicable.

The cost of equity-settled transactions is recognised, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled (the vesting period), ending on the date on which the relevant employees become fully entitled to the award (the vesting date).

At each subsequent reporting date until vesting, the cumulative charge to the statement of comprehensive income is the product of:

- (i) the grant date fair value of the award;
- (ii) the current best estimate of the number of awards that will vest, taking into account such factors as the likelihood of employee turnover during the vesting period and the likelihood of non-market performance conditions being met; and
- (iii) the expired portion of the vesting period.

The charge to the statement of comprehensive income for the period is the cumulative amount as calculated above less the amounts already charged in previous periods. There is a corresponding entry to equity.

Until an award has vested, any amounts recorded are contingent and will be adjusted if more or fewer awards are vested than were originally anticipated to do so. Any award subject to a market condition is considered to vest irrespective of whether or not that market condition is fulfilled, provided that all other conditions are satisfied.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Summary of Significant Accounting Policies (continued)

(w) Share-based payment transactions (continued)

If the terms of an equity-settled award are modified, as a minimum an expense is recognised as if the terms had not been modified. An additional expense is recognised for any modification that increases the total fair value of the share-based payment arrangement, or is otherwise beneficial to the employee, as measured at the date of modification.

If an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognised for the award is recognised immediately. However, if a new award is substituted for the cancelled award and designated as a replacement award on the date that it is granted, the cancelled and new award are treated as if they were a modification of the original award, as described in the previous paragraph.

The dilutive effect, if any, of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

(x) New Accounting Standards and Interpretations for Application in Future Periods

Accounting Standards and Interpretations issued by the AASB that are not yet mandatorily applicable to the Group, together with an assessment of the potential impact of such pronouncements on the Group when adopted in future periods, are discussed below:

AASB 2014-10: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendments to AASB 10 and AASB 128)

Amends AASB 10 and AASB 128 to remove the inconsistency in dealing with the sale or contribution of assets between an investor and its associate or joint venture. A full gain or loss is recognised when a transaction involves a business (whether it is housed in a subsidiary or not). A partial gain or loss is recognised when a transaction involves assets that do not constitute a business, even if these assets are housed in a subsidiary.

The mandatory application date of AASB 2014-10 has been amended and deferred to annual reporting periods beginning on or after 1 January 2022 by AASB 2017-5. This amended Standard is not expected to have a significant impact on the Group's financial statements.

AASB 9: Financial Instruments

AASB 9 includes requirements for the classification and measurement of financial assets and incorporates amendments to the accounting for financial liabilities and hedge accounting rules to remove the quantitative hedge effectiveness tests and have been replaced with a business model test.

AASB 9 improves and simplifies the approach for classification and measurement of financial assets compared with the requirements of AASB 139 as follows:

- a) Financial assets that are debt instruments will be classified based on (1) the objective of the entity's business model for managing the financial assets; (2) the characteristics of the contractual cash flows.
- b) Allows an irrevocable election on initial recognition to present gains and losses on investments in equity instruments that are not held for trading in other comprehensive income. Dividends in respect of these investments that are a return on investment can be recognised in profit or loss and there is no impairment or recycling on disposal of the instrument.
- c) Financial assets can be designated and measured at fair value through profit or loss at initial recognition if doing so eliminates or significantly reduces a measurement or recognition inconsistency that would arise from measuring assets or liabilities, or recognising the gains and losses on them, on different bases.
- d) Where the fair value option is used for financial liabilities the change in fair value is to be accounted for as follows:
 - i) The change attributable to changes in credit risk are presented in other comprehensive income (OCI)
 - ii) The remaining change is presented in profit or loss.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Summary of Significant Accounting Policies (continued)

(x) New Accounting Standards and Interpretations for Application in Future Periods (continued)

AASB 9: Financial Instruments

AASB 2012-6 also modifies the relief from restating prior periods by amending AASB 7 to require additional disclosures on transition to AASB 9 in some circumstances. Consequential amendments were made to other standards as a result of AASB 9 by AASB 2014-7 and AASB 2014-8. The mandatory application date of AASB 9 has been deferred to annual reporting periods beginning on or after 1 January 2018 by AASB 2014-1.

The Directors anticipate that the adoption of AASB 9 will not have any significant impact on the Group's financial instruments.

AASB 15: Revenue from Contracts with Customers

AASB 15 replaces AASB 118 Revenue, AASB 111 Construction Contracts and four Interpretations issued by the AASB and amends the principles for recognising revenue from contracts with customers. It applies to all contracts with customers except leases, financial instruments and insurance contracts. The Standard requires an entity to recognise revenue on a basis that depicts the transfer of promised goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that principle, an entity shall apply all of the following steps:

- a) identify the contract with a customer;
- b) identify the separate performance obligations in the contract;
- c) determine the transaction price;
- d) allocate the transaction price to the separate performance obligations in the contract; and
- e) recognise revenue when (or as) the entity satisfies a performance obligation.

Consequential amendments to other Standards are made by AASB 2014-5 Amendments to Australian Accounting Standards arising from AASB 15. The mandatory application date of AASB 15 has been deferred to annual reporting periods beginning on or after 1 January 2018 by AASB 2015-8.

The Directors anticipate that the adoption of AASB 15 will have an impact on the Group's financial statements, due to the recognition of anticipated sales returns in selected Asian markets and, this is currently estimated at 6% of gross annual sales of the Group. The Group has been recognising actual sales returns under the current accounting standard. The historic sales returns experienced in Asian markets has been quite consistent at about 10-12% of total Asia annual sales. The initial adoption in FY 2018 is expected to have a one-off impact of approximately \$2 million decrease in opening retained earnings, as the transitional rules of the new accounting standard allows for the initial recognition of the prior years' impact, to be recognised as an adjustment to the opening Retained Earnings at 1 January 2018.

AASB 16: Leases

AASB 16 replaces AASB 117 Leases and set out the principles for the recognition, measurement, presentation and disclosure of leases.

AASB 16 introduces a single lessee accounting model and requires a lessee to recognise assets and liabilities for all leases with a term of more than 12 months, unless the underlying asset is of low value. A lessee is required to recognise a right-of-use asset representing its right to use the underlying leased asset and a lease liability representing its obligations to make lease payments.

A lessee measures right-of-use assets similarly to other non-financial assets (such as property, plant and equipment) and lease liabilities similarly to other financial liabilities. As a consequence, a lessee recognises depreciation of the right-of-use asset and interest on the lease liability, and also classifies cash repayments of the lease liability into a principal portion and an interest portion and presents them in the statement of cash flows applying AASB 107 Statement of Cash Flows.

AASB 16 substantially carries forward the lessor accounting requirements in AASB 117 Leases. Accordingly, a lessor continues to classify its leases as operating leases or finance leases, and to account for those two types of leases differently.

This Standard applies to annual reporting periods beginning on or after 1 January 2019. Earlier application is permitted provided the entity also applies AASB 15 Revenue from Contracts with Customers at or before the same date.

Although the Directors anticipate that the adoption of AASB 16 may have an impact on the Group's financial statements, it is impracticable at this stage to provide a reasonable estimate of such impact.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Summary of Significant Accounting Policies (continued)

(x) New Accounting Standards and Interpretations for Application in Future Periods (continued)

The following new and amended Standards apply to annual reporting periods beginning on or after 1 January 2018. These new and amended Standards are not expected to have a significant impact on the Group's financial statements:

AASB 2016-3 Amendments to Australian Accounting Standards – Clarifications to AASB 15

This Standard amends AASB 15 Revenue from Contracts with Customers to clarify the requirements on identifying performance obligations, principal versus agent considerations and the timing of recognising revenue from granting a licence. In addition, it provides further practical expedients on transition to AASB 15.

AASB 2016-5 Amendments to Australian Accounting Standards – Classification and Measurement of Share-based Payment Transactions

This Standard amends AASB 2 Share-based Payment to address:

- (a) the accounting for the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments;
- (b) the classification of share-based payment transactions with a net settlement feature for withholding tax obligations; and
- (c) the accounting for a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled.

AASB 2017-1 Amendments to Australian Accounting Standards – Transfers of Investment Property, Annual Improvements 2014–2016 Cycle and Other Amendments

Clarifies that:

- a) a change in classification to or from investment property can only be made where there is evidence of a change in use of the property. A change in management's intention is, in isolation, not evidence of a change in use; and
- b) the election by a venture capital organisation, mutual fund, unit trust or similar entity to measure investments in an associate or joint venture at fair value through profit or loss is made separately for each associate or joint venture.

Interpretation 22 Foreign Currency Transactions and Advance Consideration

The Interpretation clarifies that for the purpose of determining the exchange rate to use on initial recognition of the related asset, expense or income is the date on which the entity recognises the payment or receipt of advance consideration in a foreign currency. This Standard applies to annual reporting periods beginning on or after 1 January 2018.

The following new and amended Standards apply to annual reporting periods beginning on or after 1 January 2019. These new and amended Standards are not expected to have a significant impact on the Group's financial statements:

Interpretation 23 Uncertainty over Income Tax Treatments

Interpretation 23 clarifies how to apply the recognition and measurement requirements in AASB 112 Income Taxes when there is uncertainty over income tax treatments.

Consequential amendments are made to AASB 1 First-time Adoption of Australian Accounting Standards as a result of Interpretation 23 by AASB 2017-4.

AASB 2017-6 Amendments to Australian Accounting Standards – Prepayment Features with Negative Compensation.

This Standard amends AASB 9 to permit entities to measure at amortised cost or fair value through other comprehensive income particular financial assets that would otherwise have contractual cash flows that are solely payments of principal and interest but do not meet that condition only as a result of a prepayment feature.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

(x) New Accounting Standards and Interpretations for Application in Future Periods (continued)

AASB 2017-7 Amendments to Australian Accounting Standards – Long-term Interests in Associates and Joint Ventures

This Standard amends AASB 128 to clarify that an entity is required to account for long-term interests in an associate or joint venture, which in substance form part of the net investment in the associate or joint venture but to which the equity method is not applied, using AASB 9 Financial Instruments before applying the loss allocation and impairment requirements in AASB 128.

(y) New and Amended Accounting Policies Adopted by the Group

The Group adopted the following Australian Accounting Standards from the mandatory application date of 1 January 2017:

AASB 2016-1 Amendments to Australian Accounting Standards – Recognition of Deferred Tax Assets for Unrealised Losses [AASB 112]

This Standard amends AASB 112 Income Taxes to clarify the circumstances in which the recognition of deferred tax assets may arise in respect of unrealised losses on debt instruments measured at fair value.

AASB 2016-2 Amendments to Australian Accounting Standards – Disclosure Initiative: Amendments to AASB 107

This Standard amends AASB 107 Statement of Cash Flows to include additional disclosures and reconciliation relating to changes in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes.

AASB 2015-9 Amendments to Australian Accounting Standards – Scope and Application Paragraphs

This amending Standard reinstates the scope paragraphs inadvertently deleted from AASB 8 and AASB 133. There is no change to the requirements or the applicability of AASB 8 and AASB 133.

AASB 2017-2 Amendments to Australian Accounting Standards – Further Annual Improvements 2014–2016 Cycle

Specifies that summarised financial information relating to a subsidiary, associate or joint venture is not required by AASB 12 Disclosure of Interests in Other Entities where an entity's interests in those entities are classified as held for sale, held for distribution to owners in their capacity as owners or discontinued operations in accordance with AASB 5 Non-current Assets Held for Sale and Discontinued Operations.

(z) Significant accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements and estimates on historical experience and on other various factors it believes to be reasonable under the circumstances, the result of which form the basis of the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.

Management has identified the following critical accounting policies for which significant judgements, estimates and assumptions are made. Actual results may differ from these estimates under different assumptions and conditions and may materially affect financial results or the financial position reported in future periods.

Further details of the nature of these assumptions and conditions may be found in the relevant notes to the financial statements.

Capitalised development costs

Included in intangible assets (Note 12) at the end of the year is an amount of \$60,000 (2016: \$76,000) relating to capitalised development cost. Development costs are only capitalised by the Group when it can be demonstrated that the technical feasibility of completing the intangible asset is valid so that the asset will be available for use or sale.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Summary of Significant Accounting Policies (continued)

(z) Significant accounting judgements, estimates and assumptions (continued)

Taxation

The Group's accounting policy for taxation requires management's judgement as to the types of arrangements considered to be a tax on income in contrast to an operating cost. Judgement is also required in assessing whether deferred tax assets and certain deferred tax liabilities are recognised on the statement of financial position. Deferred tax assets, including those arising from unrecouped tax losses, capital losses and temporary differences, are recognised only where it is considered more likely than not that they will be recovered, which is dependent on the generation of sufficient future taxable profits.

Judgements are also required about the application of income tax legislation. These judgements and assumptions are subject to risk and uncertainty, hence there is a possibility that changes in circumstances will alter expectations, which may impact the amount of deferred tax assets and deferred tax liabilities recognised on the statement of financial position and the amount of other tax losses and temporary differences not yet recognised. In such circumstances, some or all of the carrying amounts of recognised deferred tax assets and liabilities may require adjustment, resulting in a corresponding credit or charge to the consolidated statement of comprehensive income.

Share-based payment transactions

The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact expenses and equity.

The Group measures the cost of share-based payments at fair value at the grant date using the Black-Scholes formula taking into account the terms and conditions upon which the instruments were granted.

Estimation of useful lives of assets

The estimation of the useful lives of assets has been based on historical experience as well as manufacturers' warranties (for plant and equipment), lease terms (for leased equipment) and turnover policies (for motor vehicles). In addition, the condition of the assets is assessed at least once per year and considered against the remaining useful life. Adjustments to useful lives are made when considered necessary.

Inventory obsolescence

Inventories are stated at the lower of cost and net realisable value. The Directors assess slow moving or obsolete inventory on a regular basis and a provision is raised to write down inventory to net realisable value as described in note 1 (h).

Recoverability of associate investment in Mitre Focus Sdn Bhd

At the end of each reporting period, the Group reviews the carrying amounts of its investment in associate to determine whether there is any indication that it has suffered impairment loss. If the recoverable amount of the investment is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

2 Segment Information

Management has determined the operating segments based on the reports reviewed by the Board that are used to make strategic decisions. As the Board monitors business activity by each country the Group operates in, management has determined the Geographic Segment report to be of primary interest to users of this financial report.

Geographical segments

The consolidated entity operates in the regions identified as Australia, Singapore, Malaysia and others.

The following tables present revenue and profit information and certain asset and liability information regarding geographical segments for the years ended 31 December 2017 and 31 December 2016.

	Australia \$'000	Singapore \$'000	Malaysia \$'000	Others \$'000	Corporate \$'000	Total \$'000
Year ended 31 December 2017						
Revenue						
Sales to external customers	15,569	6,472	13,189	2,508	-	37,738
Total segment revenue	15,569	6,472	13,189	2,508	-	37,738
Segment results						
Earnings before interest and tax	3,351	1,384	1,715	(565)	(1,189)	4,696
Net interest	77	(2)	(96)	-	(1)	(22)
Share of profit of associates	-	-	-	2	-	2
Profit before income tax						4,676
Income tax expense						(1,820)
Net profit for the year						2,856
Assets and liabilities						
Segment assets	10,630	3,479	15,866	1,334	698	32,007
Investment in associates	-	-	-	947	-	947
Total assets						32,954
Segment liabilities	2,450	752	3,710	237	1,012	8,161
Total liabilities						8,161
Other segment information						
Capital expenditure	(9)	(12)	(174)	-	-	(194)
Depreciation	(8)	(20)	(261)	(34)	-	(323)
Amortisation	-	-	(11)	(3)	-	(14)

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

1 Segment Information (continued)

	Australia \$'000	Singapore \$'000	Malaysia \$'000	Others \$'000	Corporate \$'000	Total \$'000
Year ended 31 December 2016						
Revenue						
Sales to external customers	15,590	6,543	13,509	2,176	-	37,818
Total segment revenue	15,590	6,543	13,509	2,176	-	37,818
Segment results						
Earnings before interest and tax	3,873	1,530	1,788	(1,396)	(105)	5,690
Net interest	41	(3)	(99)	(3)	(1)	(65)
Share of profit of associates	-	-	-	12	-	12
Profit before income tax						5,637
Income tax expense						(2,301)
Net profit for the year						3,336
Assets and liabilities						
Segment assets	13,255	1,297	17,113	1,353	(1,584)	31,434
Investment in associates	-	-	-	925	-	925
Total assets						32,359
Segment liabilities	3,252	665	4,555	224	488	9,184
Total liabilities						9,184
Other segment information						
Capital expenditure	(9)	(17)	(2,185)	(19)	-	(2,230)
Depreciation	(8)	(14)	(192)	(32)	-	(246)
Amortisation	-	-	(17)	(3)	-	(20)

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

3 Revenue and Expenses

	2017 \$'000	2016 \$'000
(a) Other income		
Realised loss on foreign exchange	(40)	(20)
Unrealised gain on foreign exchange	17	61
Other income	24	201
	1	242
(b) Administrative expenses		
Legal and other professional fees	(355)	(385)
Consultants	(557)	(1,364)
Allowance for impairment loss	(461)	(14)
Wages, salaries and other employee expenses	(9,504)	(9,657)
Defined contribution superannuation expense	(929)	(986)
Travelling expenses	(239)	(309)
Share based payment income	139	225
Depreciation	(323)	(246)
Amortisation	(14)	(20)
Other administrative expenses	(461)	(519)
	(12,704)	(13,275)
(c) Other expenses		
Product registration costs	(411)	(365)
Loss on disposal of property, plant and equipment	(1)	(3)
	(412)	(368)
(d) Share Options expenses		
Share Options expenses	(932)	-
(e) Finance income		
Interest received - external parties	113	100
	113	100
(f) Finance expenses		
Interest expense - external parties	(97)	(112)
Bank charges	(38)	(53)
	(135)	(165)

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

4 Earnings per share

(a) Earnings used in calculating earnings per share

	2017 \$'000	2016 \$'000
Net profit attributable to equity holders from continuing operations	2,856	3,336
Earnings used to calculate basic and dilutive earnings per share	2,863	3,343

(b) Weighted average number of shares

	2017 Number	2016 Number
Weighted average number of ordinary shares for basic earnings per share	55,007,084	55,204,372
Adjusted weighted average number of ordinary shares for diluted earnings per share. In FY2017.	55,007,084	56,858,538

5 Income Taxes

a) Income Tax Expense

The major components of income tax expense are:

Income Statements:

Current income tax

Current income tax charge

1,932

1,859

Prior year under / (over) provision

(100)

428

Deferred income tax

Adjustment of deferred tax of prior periods

-

(19)

Relating to origination and reversal of temporary differences

(12)

33

Income tax expense reported in the income statement

1,820

2,301

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

5 Income Taxes (continued)

(b) A reconciliation between tax expense and the product of accounting profit before income tax multiplied by the Group's applicable income tax rate is as follows:

	2017 \$'000	2016 \$'000
Total accounting profit before income tax	4,676	5,637
At the parent entity's statutory income tax rate of 27.5% (2016: 30%)	1,286	1,691
Adjustment in respect of current income tax of previous year	(100)	428
Change in income tax rate	36	-
Foreign tax rate adjustment	(192)	(125)
Travel and staff amenities expenses	-	1
Share based payments	(38)	(68)
Share options expense	256	-
Other income/(expenditure) not allowable for income tax purposes	402	161
Adjustment of deferred tax of prior periods	-	(19)
Deferred tax asset recognised during financial year	(12)	33
Tax losses and timing differences not brought to account	182	199
Aggregate income taxes	1,820	2,301
The applicable weighted tax rates are as follows:	39%	41%

(c) Deferred income taxes at 31 December relates to the following:

<i>Deferred tax assets/ (liabilities)</i>		
Doubtful debts	5	5
Inventory obsolescence	5	15
Provision for annual leave	84	65
Provision for long service leave	31	32
Other provision	46	37
Net deferred tax assets/ (liabilities)	171	154
<i>Presented in the consolidated Statement of Financial Position as follows:</i>		
Deferred tax assets	223	205
Deferred tax liabilities	(52)	(51)
	171	154

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

5 Income Taxes (continued)

(d) Tax losses

The Group has carry forward tax losses of SGD \$17.1 million (A\$16.4m) (2016: SGD \$17.4 million (A\$16.7)) held within a wholly owned subsidiary, for which no deferred tax asset is brought to account. These losses are available indefinitely for offset against taxable income of the companies in which those losses arose subject to the meeting of the conditions required under the shareholders' continuity test. The benefit of these tax losses has not been brought to account as the probable recognition criteria has not been satisfied. Were these tax losses to be recognised, it would result in a deferred tax asset at the Singaporean company tax rate of 17%.

(e) Tax consolidation

(i) Members of the tax consolidated group and the tax sharing agreement

The Company is the head entity of the tax consolidated group comprising all the Australian wholly owned subsidiaries. The implementation date for the tax consolidated group was for the tax period ended 30 June 2003. Members of the group have entered into a tax sharing agreement that provides for the allocation of income tax liabilities between the entities should the head entity default on its tax payment obligations. No amounts have been recognised in the financial statements in respect of this agreement on the basis that the possibility of default is remote.

(ii) Tax effect accounting by members of the tax consolidated group

Measurement method adopted

The head entity and the controlled entities in the tax consolidated group continue to account for their own current and deferred tax amounts. Current and deferred tax amounts are measured in a systematic manner that is consistent with the broad principles in AASB 112 *Income Taxes*.

The current and deferred tax amounts of the members of the tax consolidated group are recognised in the separate financial statements of the members of the tax consolidated group using a "Stand-Alone Taxpayer" approach by reference to the carrying amounts of assets and liabilities in the separate financial statements of each entity and the tax values applying under consolidation.

Any current tax Australian liabilities (or assets) and deferred tax assets arising from unused tax losses of the subsidiaries is assumed by the head entity in the tax consolidated group and are recognised as amounts receivable from (payable to) other entities in the tax consolidated group. Any difference between these amounts is recognised by the head entity as an equity contribution or distribution.

The Company recognises deferred tax assets arising from unused tax losses of the tax consolidated group to the extent that it is probable that future taxable profits of the tax consolidated group will be available against which the asset can be utilised. Any subsequent period adjustments to deferred tax assets arising from unused tax losses as a result of revised assessments of the probability of recoverability is recognised by the head entity only.

Nature of the tax funding agreement

Members of the tax consolidated group have entered into a tax funding agreement, which sets out the funding obligations of members of the tax consolidated group. Payments required to / (from) head entity are equal to the current tax liability / (assets) assumed from the members of the tax consolidated group. The inter-entity receivable (payable) is at call.

Tax consolidation contributions / (distributions)

The Company has recognised the following amount as tax-consolidation contribution adjustment:

	2017 \$'000	2016 \$'000
Total increase in intercompany receivable of Vita Life Sciences Limited	1,176	1,245

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

6 Cash and cash equivalents

	2017 \$'000	2016 \$'000
Cash at bank and in hand (a)	5,644	7,697
Short term deposit (b)	4,321	1,714
Total cash and cash equivalents	9,965	9,411

(a) Cash at bank of \$5,644,000 (2016: \$7,697,000) earns interest at floating rates based on daily bank deposit rates.

(b) Short term deposit earns interest at the respective short-term deposit rates.

(c) The fair value of cash equivalents for the Group is as stated above.

(d) Reconciliation of net profit after tax to net cash flows from operations

	2017 \$'000	2016 \$'000
Net profit after tax	2,856	3,336
Adjustments for non-cash income and expense items:		
Depreciation	323	246
Amortisation	14	20
Net loss on disposal of property, plant & equipment	1	3
Share Options expense	932	-
Shared based payment (income)	(139)	(225)
Allowance for / (reversal of) impairment loss	(5)	14
	3,982	3,394
Increase/decrease in assets and liabilities:		
Decrease / (increase) in inventories	245	1,172
(Increase) / decrease in investment in associates	(2)	(12)
Decrease / (Increase) in receivables	(408)	216
Decrease / (Increase) in other assets	178	32
Decrease in deferred tax balances	(17)	32
Increase / (decrease) in current income tax payable	(968)	1,580
(Decrease) / increase in trade and other payables	205	(1,593)
(Decrease) / increase in other liabilities	(18)	(11)
Effect of foreign exchange translation of assets and liabilities	21	(116)
Net cash provided by operating activities	3,218	4,694

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

7 Trade and other receivables

	2017 \$'000	2016 \$'000
Current		
Trade receivables, third parties	5,577	4,899
Allowance for impairment loss (a)	(30)	(35)
	5,547	4,864
Other receivables:		
Other receivables (b)	1,107	1,350
Net tax receivable	8	20
	6,662	6,234

(a) Allowance for impairment loss

Trade receivables are non-interest bearing and generally on 30 to 90 day terms. A provision for impairment loss is recognised when there is objective evidence that an individual trade receivable is impaired. An impairment reversal of \$5,000 (2016: impairment benefit of \$14,000) has been recognised by the Group. These amounts have been included in the administrative expenses.

Movements in the provision for impairment loss were as follows:

	2017 \$'000	2016 \$'000
At 1 January 2017	35	21
Charge for the year	(5)	14
	30	35

(b) Other receivables are non-interest bearing and have repayment terms between 30 to 90 days. Other receivables contain an impaired asset for which an impairment loss of \$466,000 (2016: Nil) was provided during the year. It is expected that these other balances (after impairment) will be received when due.

(c) Fair value

The carrying value for trade and other receivables is assumed to approximate their fair value. The maximum exposure to credit risk is the fair value of receivables.

8 Inventories

	2017 \$'000	2016 \$'000
Current		
Raw materials at cost	1,379	1,143
Finished goods at lower of cost and net realisable value	3,797	4,278
	5,176	5,421

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

9 Other assets

	2017 \$'000	2016 \$'000
Current		
Prepayments	290	441
Security deposits	215	242
	505	683
Non- Current		
Other assets	7	23
	512	706

10 Investment in Associates

	2017 \$'000	2016 \$'000
Non-Current		
Unlisted		
-Mitre Focus Sdn Bhd (a)	947	925
(a) Details of the carrying value of investment and share of profit in associate:		
- Investment in associate at cost	-	-
-Loan to associate	900	880
-Cumulative share of associate's profit	47	45
Carrying value of investment in associate	947	925

	Measurement Method	Place of Incorporation/ Business	Ownership Interest	
			2017 %	2016 %
(b) Investment Details-Name of Company:				
Unlisted				
-Mitre Focus Sdn Bhd	Equity Method	Malaysia	6.3	6.3

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

10 Investment in Associates (continued)

(c) Summarised financial information

The following illustrates the summarised financial information relating to the Group's associate

Extract from the associate's statement of financial position:

Current Assets	6,074	5,168
Non-Current Assets	740	1,640
	6,814	6,808

Current Liabilities	(4,216)	(4,292)
Non-current liabilities	-	-
	(4,216)	(4,292)

Net assets	2,598	2,516
------------	-------	--------------

Share of associate's net assets	164	159
---------------------------------	-----	------------

Extract from the associate's income statement:

Revenue	1,819	3,190
---------	-------	--------------

Net profit	24	188
Other comprehensive income	-	-
Total comprehensive income	24	188

(d) The reporting date of the associate is 31 December 2017. The reporting date coincides with the Company's reporting date.

(e) The loan to associate is interest free and has no fixed repayment term.

(f) As at 31 December 2017, there are no contingent liabilities relating to the associate.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

11 Property, plant and equipment

	Property and Buildings \$'000	Leasehold improvements \$'000	Plant and equipment \$'000	Leased Plant and Equipment \$'000	Total \$'000
Year ended 31 December 2017					
At 1 January 2017 net of accumulated depreciation and impairment	8,521	12	826	22	9,381
Additions	101	14	80	-	195
Exchange differences	156	(1)	1	-	157
Depreciation / amortisation for the year	(90)	(13)	(209)	(11)	(323)
At 31 December 2017 net of accumulated depreciation and impairment	8,688	12	698	11	9,409
At 31 December 2017					
Cost value	8,816	96	2,043	145	11,101
Accumulated depreciation and impairment	(128)	(84)	(1,345)	(134)	(1,691)
Net carrying amount	8,688	12	698	11	9,409

	Property and Buildings \$'000	Leasehold improvements \$'000	Plant and equipment \$'000	Leased Plant and Equipment \$'000	Total \$'000
Year ended 31 December 2016					
At 1 January 2016 net of accumulated depreciation and impairment	7,316	13	266	34	7,629
Additions	1,444	11	759	-	2,214
Disposals	-	-	(2)	-	(2)
Exchange differences	(206)	(1)	(1)	(6)	(214)
Depreciation / amortisation for the year	(33)	(11)	(196)	(6)	(246)
At 31 December 2016 net of accumulated depreciation and impairment	8,521	12	826	22	9,381
At 31 December 2016					
Cost value	8,551	83	1,945	146	10,725
Accumulated depreciation and impairment	(30)	(71)	(1,119)	(124)	(1,344)
Net carrying amount	8,521	12	826	22	9,381

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

12 Intangible assets

	Product Development costs \$'000	Total \$'000
Year ended 31 December 2017		
At 1 January 2017 net of accumulated depreciation and impairment	76	76
Additions		-
Impairment / amortisation	(14)	(14)
Exchange differences	(2)	(2)
At 31 December 2017 net of accumulated depreciation and impairment	60	60
At 31 December 2017		
Gross carrying amount	178	178
Accumulated amortisation and impairment	(118)	(118)
Total	60	60

	Product Development costs \$'000	Total \$'000
Year ended 31 December 2016		
At 1 January 2016 net of accumulated depreciation and impairment	86	86
Additions	16	16
Impairment / amortisation	(20)	(20)
Exchange differences	(6)	(6)
At 31 December 2016 net of accumulated depreciation and impairment	76	76
At 31 December 2016		
Gross carrying amount	291	291
Accumulated amortisation and impairment	(215)	(215)
Total	76	76

Development costs

Development costs are carried at cost less accumulated amortisation and accumulated impairment losses. This intangible asset has been assessed as having a finite life and is amortised using the straight line method over a period of 3 years. The amortisation has been recognised in the statement of comprehensive income in the line item 'administrative expense'. If an impairment indication arises, the recoverable amount is estimated and an impairment loss is recognised to the extent that the recoverable amount is lower than the carrying amount.

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

13 Trade and other payables

	2017 \$'000	2016 \$'000
Current		
Trade payables (a)	2,455	1,287
Net tax payable	252	264
Other payables and accruals	1,706	2,657
	4,413	4,208

(a) Trade payables are non-interest bearing and are normally settled within 90-day terms. Other payables are non-interest bearing and have an average term of 3 months.

14 Interest bearing loans and borrowings

	2017 \$'000	2016 \$'000
Current		
Property facility - secured (a)	290	279
	290	279
Non - Current		
Property facility - secured (a)	1,927	2,181
	1,927	2,181
At the balance date, the following financing facilities were available:	2017	2016
	\$'000	\$'000
Total facilities available:		
Property facility (a)	3,042	2,984
Bank overdrafts (b)	-	200
	3,042	3,184
Facilities utilised at balance date:		
Property facility (a)	2,217	2,460
Facilities not utilised at balance date:		
Property facility (a)	825	524
Bank overdrafts (b)	-	200
	825	724

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

14 Interest bearing loans and borrowings (continued)

(a) Property finance facility

Trade property facility is provided by a Malaysian bank to the Group's main operating subsidiary in Malaysia. The interest rate for the facility as at 31 December 2017 was fixed at 4.25% (2016: 4.25%) for a further term of 108 months from 1 January 2015. The facility is secured by a charge over the premises.

(b) Bank overdrafts

During the year, the Bank Overdraft facility was cancelled at the request of the Company. Interest on bank overdrafts was charged at prevailing market rates. The weighted average interest rate for the overdraft as at 31 December 2017 was Nil (2016: 9.47% p.a.) The bank overdraft of the controlled entity was secured by way of a pledge of the short term deposits of the controlled entity.

(c) Default and breaches

During the current and prior year, there were no defaults or breaches on any of the loans.

15 Provisions

(a) Employee entitlements

Provision is made for employee benefits accumulated as a result of employees rendering services up to the reporting date. These benefits include wages and salaries, annual leave and long service leave.

	Employee Entitlements \$'000	Total \$'000
Consolidated		
Balance at 1 January 2017	707	707
Charged during year	757	757
Used during year	(768)	(768)
Foreign exchange difference	(7)	(7)
Balance at 31 December 2017	689	689
At 31 December 2017		
Current	586	586
Non-Current	103	103
	689	689
At 31 December 2016		
Current	602	602
Non-Current	105	105
	707	707

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

16 Contributed equity

	2017 Number	2016 Number	2017 \$	2016 \$
Issued and paid up capital				
Ordinary shares	56,717,026	55,908,230	44,498,322	44,691,656
Ordinary shares				
Balance at beginning of the year	55,908,230	57,197,839	44,691,656	44,911,156
Share buy back (a)	(191,204)	(167,109)	(193,334)	(219,500)
Cancellation of Plan Shares of certain:				
- Employees and Directors (b)	-	(1,122,500)	-	-
Issue of shares to employee / director (c)	1,000,000	-	-	-
Balance at end of the year	56,717,026	55,908,230	44,498,322	44,691,656

(a) Share Buy-Back

A total of 191,204 (2016: 167,109) ordinary shares were bought back for year ended 31 December 2017 as approved by the shareholders in the 18 May 2017 and 12 May 2016 Annual General Meetings at a total cost of \$193,334 (2016: \$219,500).

(b) Cancellations of Long Term Incentive Plan Shares to key executives

In 2016, 882,500 Long Term Incentive Plan shares were cancelled as the 2015 and 2016 financial year performance conditions were not achieved. A further 240,000 shares were cancelled due to the retirement of a senior executive.

(c) Issue of Long Term Incentive Plan Shares to key executives

During the year ended 31 December 2017, the Company approved loans to the Managing Director Mr Andrew O'Keefe totalling \$1,380,000 in order for Mr O'Keefe to purchase a total of 1,000,000 shares under the Company's Long Term Incentive Plan.

For the full year ended 31 December 2017, the Company recognised net income of \$138,964 (2016: \$225,071) in the income statement with a corresponding decrease (2016: decrease) in employee share based payment reserve.

(d) Share Options

On 3 January 2017, unlisted options convertible to ordinary shares in the Company were granted as a key incentive to Mr Liyang Liu, a key executive based in China, as per Options Deed dated 3 January 2017, as set out below:

Tranche	Number Granted	Grant Date	Exercise Price-\$	Fair Value at Grant Date		First Vesting Date	Expiry Date
				Per right-\$	Value-\$		
1	2,208,000	3/01/2017	1.2750	0.3020	666,816	from the date of the Option Deed	3/01/2018
2	1,106,000	3/01/2017	2.0000	0.1514	167,448	12 months from the date of the Option Deed	3/07/2018
3	1,106,000	3/01/2017	2.5000	0.1426	157,716	18 months from the date of the Option Deed	3/01/2019
	<u>4,420,000</u>				<u>991,980</u>		

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

16 Contributed equity (continued)

(d) Share Options (continued)

During the year ended 31 December 2017, a sum of \$ 931,782 was expensed as Share Option expense. Tranche 1 of the Options had not been exercised and therefore lapsed on 3 January 2018.

The remaining balance of the fair value of the options at Grant Date of \$60,198 will be expensed in the financial year ending 31 December 2018.

(e) Capital management

When managing capital, management's objective is to ensure the Company continues as a going concern as well as to maintain optimal returns for shareholders and benefits for other stakeholders. Management also aims to maintain a capital structure that ensures the lowest cost of capital available to the entity.

Management constantly assesses the capital structure to take advantage of favourable costs of capital and / or high returns on assets. As the market is continuously changing, management may issue dividends to shareholders, return capital to shareholders, issue new shares, increase the short or long term borrowings or sell assets to reduce borrowings.

(f) Dividends

The Directors declared a fully franked interim dividend of 1.5 cents per share and a fully franked final dividend of 2.25 cents per share in respect of the financial year ended 31 December 2017 (2016: interim dividend of 1.5 cents unfranked and an unfranked final dividend of 2.25 cents).

The final dividend of 2.25 cents per share has not been recognised in these consolidated financial statements as it was declared subsequent to 31 December 2017.

	2017 Cents per Share	2016 Cents per Share	2017 \$'000	2016 \$'000
Fully paid ordinary shares				
Final dividend for the previous financial year				
- No franking credits attached	2.25	2.25	1,239	1,243
Interim dividend for the financial year				
- Full franking credits attached	1.50	-	825	-
- No franking credits attached	-	1.50	-	827
	3.75	3.75	2,063	2,070

17 Net tangible assets per share

	2017 \$	2016 \$
Net assets per share	0.44	0.41
Net tangible assets per share	0.43	0.41
	Number	Number
Number of ordinary shares for net assets per share	56,717,026	55,908,230

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

18 Subsidiaries

Name	Place of Incorporation	Percentage of Equity Interest	
		2017 %	2016 %
Tetley Research Pty Limited	Australia	100	100
Tetley Treadmills Pty Limited	Australia	100	100
Tetley Manufacturing Pty Limited	Australia	100	100
Vimed Bio Sciences Pty Limited	Australia	100	100
Allrad No 19 Pty Limited	Australia	100	100
Lovin Pharma International Limited	Ireland	100	100
Herbs of Gold Pty Limited	Australia	100	100
Herbs of Gold (Shanghai) Co. Limited	People's Republic of China	100	100
VitaHealth Laboratories Australia Pty Limited	Australia	100	100
Vita Institute of Health Pty Ltd	Australia	100	100
VitaHealth Australia Pty Ltd	Australia	100	100
Vita Corporation Pte Limited	Singapore	100	100
Herbs of Gold (S) Pte Ltd	Singapore	100	100
VitaHealth Laboratories (HK) Limited	Hong Kong	100	100
Vita Healthcare Asia Pacific Sdn Bhd	Malaysia	100	100
VitaHealth Malaysia Sdn Bhd (formerly known as Swiss Bio Pharma Sdn Bhd)	Malaysia	100	100
VitaHealth Biotech Sdn Bhd	Malaysia	100	100
Vita Lifesciences Sdn Bhd	Malaysia	100	100
Vita Science Sdn Bhd	Malaysia	100	100
Herbs of Gold Sdn Bhd	Malaysia	100	100
VitaHealth Asia Pacific (S) Pte Limited	Singapore	100	100
Vita Life Sciences (S) Pte Limited	Singapore	100	100
VitaHealth IP Pte Limited	Singapore	100	100
Vita Life Sciences (Thailand) Co. Ltd	Thailand	49	49
VitaHealth (Thailand) Co. Ltd	Thailand	74	74
Vita Health Vietnam Company Limited	Vietnam	100	100
Sino Metro Developments Limited	British Virgin Island	100	100
VitaHealth (Macao Commercial Offshore) Limited	Macao	100	100
Pharma Direct Sdn Bhd	Malaysia	100	100
PT. Vita Health Indonesia	Indonesia	100	100

Notes to the Financial Statements (Continued)

For the Year Ended 31 December 2017

19 Subsequent events

On 3 January 2018, Tranche 1 comprising 2,208,000 share options granted to Group executive, Mr Liyang Liu, expired as they had not been exercised.

On 22 February 2018, the Directors declared a final fully franked dividend of 2.25 cents per share in respect of the financial year ended 31 December 2017.

Other than the above matters, there are no subsequent events after balance date that affect the operating results or financial position of the Company and its subsidiaries.

20 Contingent assets and liabilities

The Group has no contingent assets or liabilities as at 31 December 2017.

21 Information on audit or review

This preliminary final report is based on accounts to which one of the following applies:

- | | |
|---|-------------------------------------|
| The accounts have been audited | <input type="checkbox"/> |
| The accounts have been subject to review | <input type="checkbox"/> |
| The accounts are in the process of being audited or subject to review | <input checked="" type="checkbox"/> |
| The accounts have not yet been audited or reviewed | <input type="checkbox"/> |

Description of likely dispute or qualification if the accounts have not yet been audited or subject to review or are in the process of being audited or subjected to review.

None noted.

Compliance Statement

1. This report has been prepared in accordance with ASX Listing Rule 4.3A, Australian Accounting Standards (including Australian Accounting Interpretations) and other standards acceptable to the ASX.
2. This report, and the financial statements upon which the report is based, use the same accounting policies.
3. This report does give a true and fair view of the matters disclosed.
4. This report is based on financial statements which are in the process of being audited, and the audit report is not expected to contain any qualifications.
5. The entity has a formally constituted Audit Committee.



Chin L Khoo
Company Secretary
22 February 2018